Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Bo Didley who wrote (1625)	11/18/1999 10:09:00 PM
From: Street Walker	Respond to of 5582

"orders of Zicam(TM) have substantially exceeded five times the level of sales for the third quarter. " GUMM is way undervalued. It is growing faster than KIDE was growing one year ago. This company will exceed anyone's expectations in the long term. Well not everyone's<g> cause several of us are expecting a very significant percent gain after several splits in years to come. And this is just from the Zicam market. Wait until the nicotine gum starts bringing in sales! Regards, S.W.